J Korean Surg Soc.
1998 Jun;54(Suppl):975-982.
Ki-67 Labeling Index as a Measure of Cell Proliferative Activity in Gastric Cancer and It's Significance
- Affiliations
-
- 1Department of Surgery, Dankook University College of Medicine.
- 2Department of Surgery, Seoul National University College of Medicine.
- 3Department of Pathology, Seoul National University College of Medicine.
Abstract
-
Various methods were used to estimate the proliferative activity of tumor cells, including the Ki-67
labeling index, proliferating cell nuclear antigen the Brdurd labeling technique, the mitotic index, and
flow cytometric analysis. Several recent reports have indicated that these parameters of cellular
proliferation may be of some prognostic significance. In this study, cellular proliferative activities in
105 gastric cancer patients were analyzed with various clinicopathologic factors by using the ki-67
labeling index. The monoclonal antibody to the Ki-67 antigen detects a nuclear antigen expressed in
all phases of the cell cycle except G0, and has been widely used to determine the proliferative activity
of neoplastic tissues. The Ki-67 labeling index (the number of Ki-67 positive tumor cells divided by
the sum of Ki-67 positive and negative tumor cells) was derived by counting 1,000 cells in each case.
A significant difference was noted between advanced and early gastric cancer. Advanced gastric cancer
lesions showed a mean value of 32.15, about 1.7 times greater than that of the early gastric cancer lesions,
18.32 (p=0.001). The presence or absence of lymph node metastasis also showed a significant difference.
The mean value of Ki-67 with lymph node metastasis was 31.78 whereas that without metastasis was
19.48 (p=0.001). There was also a significant difference in Ki-67 LI between each stage (p=0.010).
However, no statistically significant differences were noted in age, sex, tumor location, histological
differentiation, lauren type, and tumor size.
Conclusion
: High Ki-67 LI may suggest active cellular proliferation and increased risk of advanced
cancer and lymph node metastasis. Ki-67 LI may be used as a possible independent parameter to predict
the outcome of gastric cancer treatment.